FDA may approve a Biologics License Application if the biologic proves to be?

Effective only

Safe and effective

A Biologics License Application (BLA) is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce. For the FDA to approve a BLA, the biologic must demonstrate that it is both safe and effective.

Safety refers to the absence of harmful side effects or adverse events when the biologic is used as intended. Effectiveness indicates that the biologic achieves its intended purpose, such as preventing disease or treating a condition. Only when both of these standards are met can the FDA ensure that the benefits of the biologic outweigh any potential risks to patients.

While other considerations, such as economic viability or general benefit, may play a role in the broader context of drug development and market access, they are not central to the FDA's decision-making process regarding the approval of a biologic. Therefore, safe and effective is the clear standard required for approval of a BLA by the FDA.

Beneficial

Economically viable

Want more questions?

All options are one-time payments.

$25.99

30 day premium pass

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99 $171.99 usd

6 month DELUXE pass (most popular)

Everything with the 30 day premium pass FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • Everything included in the premium pass
  • $171.99 usd value for $59.99! You save $106!
  • + Access to the ultimate digital PDF study guide
  • + 6 months of premium pass access
  • + Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy